C9orf72 repeat expansion is the most common known genetic cause of familial amyotrophic lateral sclerosis and frontotemporal dementia, and a major molecular bridge across the ALS-FTD spectrum.[1][1:1] Pathogenic GGGGCC repeat expansions in the first intron/promoter region drive a mixed loss-of-function and toxic gain-of-function biology involving RNA foci, dipeptide repeat proteins (DPRs), nucleocytoplasmic transport failure, and impaired proteostasis.[2][3][4]
The normal C9orf72 repeat tract is short, while pathogenic alleles contain large expansions (often hundreds to thousands of repeats). Detection strategies include repeat-primed PCR and long-read approaches for difficult borderline alleles.[1:2][5]
Key architecture points:
Clinical expression ranges from pure motor neuron disease to behavioral/cognitive syndromes, frequently within one pedigree, reinforcing shared upstream mechanisms.[1:3][6]
C9orf72 protein forms a complex with SMCR8 and WDR41 that regulates endolysosomal trafficking and autophagy initiation, with additional roles in immune signaling and lysosomal homeostasis.[7][8] In neurons and myeloid-lineage cells, reduced C9orf72 expression can impair cargo clearance and stress adaptation, sensitizing systems already burdened by repeat toxicity.[7:1][9]
Expanded sense and antisense transcripts form nuclear RNA foci that sequester RNA-binding proteins and alter splicing/translation programs.[2:1][10] This mechanism can operate early, before frank neuronal loss.
Repeat-associated non-AUG translation produces poly-GA, poly-GR, poly-PR, poly-GP, and poly-PA peptides. Arginine-rich DPRs (GR/PR) disrupt ribosomal function[8:1], phase-separated organelles, and nucleolar biology.[3:1][12][13]
C9-related RNA and DPR species interfere with nuclear pore and transport factors, resulting in impaired protein/RNA trafficking and downstream stress responses[10:1].[4:1][^14]
Lower C9orf72 expression can independently perturb lysosomal and immune pathways, especially in microglia, potentially amplifying neuroinflammatory loops in ALS-FTD[3:2].[8:2][9:1]
C9 carriers often present with limb or bulbar ALS, faster decline in subsets, and higher probability of cognitive/behavioral involvement compared with non-carriers.[6:1][^15]
Behavioral variant FTD is common, with disinhibition/apathy syndromes and early executive dysfunction. Language variants also occur but are less frequent than in GRN-linked disease.[1:4][^15]
The expansion is associated with psychosis and other neuropsychiatric features in a subset of families, emphasizing the need for broad phenotyping in precision trial enrollment.[^16]
C9orf72 is one of the best examples of a genetically defined precision-neurology target in neurodegeneration:
ASO strategies aim to reduce repeat-containing transcripts and downstream DPR production. Early trials established feasibility and target engagement, while efficacy optimization remains an active area.[17][19]
Programs targeting repeat RNA structures, RAN translation, and stress granule dynamics are under development in preclinical and translational pipelines.[10:2][^13]
Because C9 disease combines RNA toxicity, proteostasis failure, and neuroinflammation, combination strategies (repeat suppression plus clearance/inflammation modulation) are biologically plausible and increasingly prioritized.[8:3][9:2][^19]
| Mechanism | Toxic Species | Cellular Effect | Therapeutic Target |
|---|---|---|---|
| RNA toxicity | Sense/antisense foci | RBP sequestration | ASO therapy |
| DPR translation | poly-GR, poly-PR | Ribosome stalling | Translation modulators |
| Loss of function | C9orf72 reduction | Autophagy failure | Gene therapy |
A 2025 study examined whether intermediate C9orf72 repeat expansions represent a genetic risk factor for progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), corticobasal degeneration (CBD), and atypical parkinsonism [1].
The PROSPECT study analyzed 626 clinical cases (366 PSP, 130 CBS, 53 atypical parkinsonism) plus 77 pathologically confirmed CBD cases:
Intermediate C9orf72 repeat expansions do not appear to be a genetic risk factor for PSP, CBS, CBD, or atypical parkinsonism. Pathogenic hexanucleotide repeat expansions remain the most common genetic cause of frontotemporal dementia and amyotrophic lateral sclerosis, but intermediate repeats do not contribute to these atypical Parkinsonian disorders.
Singh J et al. PAICS mediates DNA damage and cerebellar neuronal loss in C9orf72 amyotrophic lateral sclerosis. Brain. 2026. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Li Y et al. Ginsenoside compound K inhibited the gelation of GGGGCC repeats and regulated co-aggregation with arginine-rich poly-dipeptides in C9orf72-related ALS. International Journal of Biological Macromolecules. 2026. ↩︎ ↩︎
Kurdi MA et al. Amyotrophic Lateral Sclerosis (ALS) Genetics and Microbiota: A Comprehensive Review. International Journal of Molecular Sciences. 2026. ↩︎ ↩︎ ↩︎
Luong DT et al. PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice. International Journal of Molecular Sciences. 2026. ↩︎ ↩︎
Russell KA et al. Intrathecal (G(4)C(2))(149) delivery in C9orf72-deficient mice yields mild motor dysfunction and ALS/FTD pathological hallmarks. bioRxiv. 2026. ↩︎
Inami S et al. Increased neuronal activity restores circadian function in Drosophila models of C9orf72-ALS/FTD. iScience. 2026. ↩︎ ↩︎
Huang S et al. Behavioral Variant Frontotemporal Dementia With C9orf72 Intermediate Repeat Expansion: A case report. Alzheimer Disease & Associated Disorders. 2026. ↩︎ ↩︎
Jiang X et al. Blocking RAN translation without altering repeat RNAs rescues C9ORF72-related ALS and FTD phenotypes. Science. 2026. ↩︎ ↩︎ ↩︎ ↩︎
Ross D et al. Thermally activated history-dependent homogenization of G-quadruplexes in an ALS/FTD-associated gene. Biophysical Journal. 2026. ↩︎ ↩︎ ↩︎
Lian L et al. Aberrant CDK4/6-driven cell-cycle reentry drives neuronal loss and defines a therapeutic target in C9orf72 ALS/FTD. iScience. 2026. ↩︎ ↩︎ ↩︎